Compare Amylx Pharmaceuticals Inc (AMLX) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.55 (market cap $2.64B), while Starbucks Corp trades at $108.12 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 46.1× Amylx Pharmaceuticals Inc's market cap, and Starbucks Corp pays a 2.33% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SBUX | |
|---|---|---|
Market Cap | $2.64B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $108.37 |
52-Week Low | $7.82 | $78.46 |
Enterprise Value | $2.39B | $140.42B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Starbucks (SBUX) trades at $107.57, up 2.79% today, showing strong momentum near its 52-week high. The stock benefits from a bullish technical outlook and improved quarterly earnings, with Q2 2026 EPS beating estimates at $0.85 vs. $0.66 expected. Revenue trends are positive, with 2025 revenue reaching $37.18B, though net income margin declined to 5.17%. Recent news highlights a turnaround in traffic and margin expansion, supported by new product launches like carbonated refreshers and seasonal offerings.
The outlook for SBUX is cautiously optimistic, with analyst consensus pointing to a $113.60 price target. Key opportunities include sustained traffic recovery and cost efficiency gains, but risks remain from high valuation (P/E 61.65) and competitive pressures. Investors should weigh the earnings rebound against premium multiples and monitor execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
